Phathom Pharmaceuticals (NASDAQ:PHAT) traded higher on Friday after Cantor Fitzgerald initiated its coverage with an overweight recommendation despite a recent selloff attributed to the company's IP ...

Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently ...

Pam Bondi, President-elect Donald Trump's choice to lead the Justice Department as attorney general, stands for a break ...

And now, amid the fallout, finger pointing has begun inside the administration, sources said, with the attention turning to Mark Paoletta, OMB's general counsel, who played a key role in drafting ...

On Friday, Cantor Fitzgerald reaffirmed its Overweight rating on Cipher Mining shares (NASDAQ:CIFR), with a set price target of $11.00. The firm's analyst, Brett Knoblauch, provided insight into ...

In a report released yesterday, C J Muse from Cantor Fitzgerald maintained a Hold rating on KLA (KLAC – Research Report), with a price target of $875.00. The company’s shares closed yesterday ...

Cantor Fitzgerald LP ’s lawsuit alleging a firm founded by four of its former investment bankers stole clients worth millions of dollars in profit was dismissed by a New York judge. Justice Nancy ...

In a report released yesterday, Colin Canfield from Cantor Fitzgerald maintained a Buy rating on Planet Labs PBC (PL – Research Report), with a price target of $6.30. The company’s shares ...

Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. As of January 29, 2025, the average one-year ...

The billionaire tapped to head up President Donald Trump’s Commerce Department has vowed to sell his business holdings within 90 days as he pursues senatorial confirmation. Howard Lutnick ...